In vitro data revealed that CRTC1 in NSCLC cells upregulates PD-L1 by directly targeting the Notch1/Akt signaling pathway, thereby suppressing T-cell survival and cytotoxic activity, ultimately triggering tumor reprogramming in NSCLC cells. The gene discussed is CRTC1; the disease is neoplasm.